Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Active not recruiting 20Recruiting 15Completed 4Terminated 3Withdrawn 2Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Pancreatic Neoplasms 5Prostatic Neoplasms 4Lung Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Multiple Myeloma 3Melanoma 3Carcinoma, Intraductal, Noninfiltrating 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Thrombocytosis 2Stomach Neoplasms 2Myeloproliferative Disorders 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma, Kaposi 1Sarcoma 1Rhabdomyosarcoma 1Resectable Pancreatic Carcinoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Specimen Handling × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

NCT04892264 2025-05-18

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Mayo Clinic

Phase 1 Terminated
5 enrolled
Plasma cell

Multiple Myeloma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡